Heroku co-founder and philanthropist Adam Wiggins has issued a $50,000 match challenge. Every dollar contributed by March 31 is matched dollar-for-dollar. These funds support CPP's 2026 Oregon legislative advocacy initiative, aimed at securing a $1 million state appropriation to make psilocybin-assisted therapy accessible to Oregonians who stand to benefit most but cannot afford it.
Your gift directly funds the work that moves that appropriation forward:
The evidence already points toward yes on both effectiveness and cost. This campaign is how we put it in front of the people who can act on it.
Oregon has now served more than 18,000 people through its licensed psilocybin therapy program. They arrived carrying depression that medication couldn't touch, trauma that talk therapy hadn't reached, addiction that had survived every prior attempt at treatment. Many described what followed as transformative in ways they didn't think were still possible.
Oregon proved—without federal intervention and without a single comparable model to follow—that safe, legal, regulated psilocybin therapy was achievable. With a 0.1% emergency response rate across three years of real-world operation, Oregon set the national safety standard other states are now following.
The question Oregon now faces is whether that healing reaches only those who can afford it—or whether the state uses what it built to help the people who need it most. State funding for treatment is the biggest unrealized opportunity in the psychedelic space today. 2026 is the year CPP builds the case. 2027 is the year we win it.
We develop health economic analyses showing that psilocybin-assisted therapy can match or beat the cost of existing treatments—giving legislators the evidence they need to act.
We develop state-funded access models grounded in evidence, implementation constraints, and real budget realities—translating clinical promise into durable public investment.
We help states avoid regulatory pitfalls that raise costs, narrow access, or undermine political support—so programs scale instead of stall.
CPP is led by Sam Chapman, campaign manager for Measure 109—the ballot initiative that launched Oregon's psilocybin program—and a legislative advocate inside the Oregon legislature since 2013. CPP's advisory board includes Dr. Bruce Goldberg, former founding director of the Oregon Health Authority; Ethan Nadelmann, founder of the Drug Policy Alliance; and Nate Howard, co-creator of InnerTrek, the country's first licensed psilocybin facilitator training program.
Oregon proved that safe, legal, regulated psilocybin therapy is achievable. Now CPP is taking the next question to the 2027 legislature: can the state use what it built to reach Oregonians who can't afford it? CPP is advancing a $1 million Oregon legislative appropriation to fund psilocybin-assisted therapy for Medicaid patients, focused on treatment-resistant depression, alcohol use disorder, and tobacco dependence.
CPP is actively working with policymakers in states where legislative interest, agency engagement, and political alignment create near-term opportunities. Conversations are already underway with potential bill sponsors and executive offices. Oregon's real-world data provides the evidentiary foundation other states can build on—reducing the cost and risk of acting.
CPP distills lessons from Oregon and Colorado into practical guidance that helps other states avoid costly missteps. In its first year, CPP published the National Psychedelic Landscape Assessment—the first comprehensive analysis of state psychedelic legislation focused on access, implementation, and public investment. That work continues in 2026.
The clinical case is made. The program exists. The political conditions are right. Your investment is the missing piece: the philanthropic commitment that gets CPP to the Oregon legislature with the evidence, the relationships, and the sustained advocacy to win.
Thousands of Oregonians have experienced what this program can do. Hundreds of thousands more need access and cannot afford it. A $1 million state appropriation changes that, and 2026 is the year we build the case to win it in 2027.
To discuss CPP's 2026 work or learn more about making a matched gift, contact our founder and executive director.
The Center for Psychedelic Policy is a 501(c)(3) non-profit, non-partisan organization providing policy analysis, technical assistance, and implementation guidance.